Cita APA

Cabello Úbeda, A., Quirós, J. C. d., Martín Carbonero, L., Sanz Sanz, J., Vergas, J., Mena, Á., . . . Górgolas Hernández-Mora, M. (2022). 48-Week effectiveness and tolerability of dolutegravir (DTG) + lamivudine (3TC) in antiretroviral-naïve adults living with HIV: A multicenter real-life cohort.

Citación estilo Chicago

Cabello Úbeda, Alfonso, et al. 48-Week Effectiveness and Tolerability of Dolutegravir (DTG) + Lamivudine (3TC) in Antiretroviral-naïve Adults Living With HIV: A Multicenter Real-life Cohort. 2022.

Cita MLA

Cabello Úbeda, Alfonso, et al. 48-Week Effectiveness and Tolerability of Dolutegravir (DTG) + Lamivudine (3TC) in Antiretroviral-naïve Adults Living With HIV: A Multicenter Real-life Cohort. 2022.